Spectral AI to Participate in the Northland Capital Markets Virtual Growth Conference
Spectral AI (Nasdaq: MDAI) will participate in the Northland Capital Markets Virtual Growth Conference on June 25, 2024. CEO Peter M. Carlson and CFO Vincent S. Capone will engage in virtual one-on-one meetings with institutional investors.
The company's DeepView™ System, which leverages multispectral imaging and a database of over 340 billion clinically validated data points, aims to distinguish between healthy and damaged tissue for better wound care decisions.
In February 2024, Spectral AI received UKCA authorization for the DeepView™ System for burn indications and anticipates generating its first commercial revenue this year. The company plans to file additional regulatory submissions in the UK and US in 2024 and 2025, with expectations to expand its commercial revenue platforms over the next two years.
- Spectral AI received UKCA authorization for its DeepView™ System in February 2024.
- The company expects to generate its first commercial product revenue this year.
- Plans to file additional UK and US regulatory submissions in 2024 and 2025.
- Anticipates expanding commercial revenue platforms over the next two years.
- The company has yet to generate any commercial product revenue.
- Regulatory approvals still pending for broader use in the UK and US.
DALLAS, June 17, 2024 (GLOBE NEWSWIRE) -- Spectral AI, Inc. (Nasdaq: MDAI) (“Spectral AI” or the “Company”), an artificial intelligence (AI) company focused on medical diagnostics for faster and more accurate treatment decisions in wound care, today announced that it will participate in the Northland Capital Markets Virtual Growth Conference on Tuesday, June 25, 2024.
Spectral AI CEO Peter M. Carlson and Chief Financial Officer Vincent S. Capone will host virtual one-on-one meetings with institutional investors throughout the day.
Spectral AI’s DeepView™ System utilizes proprietary multispectral imaging, trained and tested against a proprietary database of more than 340 billion clinically validated data points, to distinguish between healthy and damaged tissue to deliver a rapid and objective assessment as to whether a burn wound will heal naturally or requires surgical intervention.
In February 2024, the Company received UK Conformity Assessed (UKCA) authorization for the DeepView™ System for burn indication and expects to generate its first commercial product revenue later this year. Spectral AI is on track to file additional UK and US regulatory submissions in 2024 and 2025 for the approval of the DeepView™ System and expects to expand its commercial revenue platforms over the next two years.
For more information on the Northland Capital Markets Virtual Growth Conference, or to schedule a one-on-one meeting with Spectral AI management, please contact your Northland representative or The Equity Group.
About Spectral AI
Spectral AI, Inc. is a Dallas-based predictive AI company focused on medical diagnostics for faster and more accurate treatment decisions in wound care, with initial applications involving patients with burns and diabetic foot ulcers. The Company is working to revolutionize the management of wound care by “Seeing the Unknown®” with its DeepView™ System. The DeepView™ System is a predictive device that offers clinicians an objective and immediate assessment of a wound’s healing potential prior to treatment or other medical intervention. With algorithm-driven results and a goal to change the current standard of care, the DeepView™ System is expected to provide faster and more accurate treatment insight towards value care by improving patient outcomes and reducing healthcare costs. For more information about the DeepView™ System, visit www.spectral-ai.com.
Forward-Looking Statements
Certain statements made in this release are “forward-looking statements” within the meaning of the “safe harbor” provisions of the United States Private Securities Litigation Reform Act of 1995, including statements regarding the Company’s strategy, plans, objectives, initiatives and financial outlook. When used in this press release, the words “estimates,” “projected,” “expects,” “anticipates,” “forecasts,” “plans,” “intends,” “believes,” “seeks,” “may,” “will,” “should,” “future,” “propose” and variations of these words or similar expressions (or the negative versions of such words or expressions) are intended to identify forward-looking statements.
These forward-looking statements are not guarantees of future performance, conditions or results, and involve a number of known and unknown risks, uncertainties, assumptions and other important factors, many of which are outside Company’s control, that could cause actual results or outcomes to differ materially from those discussed in the forward-looking statements. As such, readers are cautioned not to place undue reliance on any forward-looking statements.
Investors should carefully consider the foregoing factors and the other risks and uncertainties described in the “Risk Factors” sections of the Company’s filings with the SEC, including the Registration Statement and the other documents filed by the Company. These filings identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements.
Investors:
The Equity Group
Devin Sullivan
Managing Director
dsullivan@equityny.com
Conor Rodriguez
Analyst
crodriguez@equityny.com
FAQ
What is Spectral AI's stock symbol?
When will Spectral AI participate in the Northland Capital Markets Virtual Growth Conference?
What technology does Spectral AI's DeepView™ System use?
Has Spectral AI received any regulatory approval for the DeepView™ System?
When does Spectral AI expect to generate its first commercial product revenue?
What are Spectral AI's future regulatory plans?
Who will be representing Spectral AI at the Northland Capital Markets Virtual Growth Conference?
